Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Xintela presents the plans for 2022 in its Q4 report

Xintela recently published its fourth quarter report, which describes the company’s plans for 2022. During the year, the stem cell product XSTEM will enter clinical trial for the first time in humans in two different phase I/IIa clinical studies; one in knee osteoarthritis and one in difficult-to-heal leg ulcers, the latter of which will be partly financed by a grant of 4.8 MSEK from Vinnova.Read the full article at biostock.se: https://www.biostock.se/en/2022/03/xintela-presents-the-plans-for-2022-in-its-q4-report/ This is a press release from BioStock - Connecting Innovation &

Members of the board of directors and major shareholders of Veg of Lund intends to exercise warrants of series TO1

Board members and major shareholders in Veg of Lund AB (publ) (“Veg of Lund” or the “Company”) intends to exercise their warrants of series TO1 that were issued during the third quarter of 2021 (“Warrants”). The subscription period for TO1 began 25 February 2022 and runs up to and including 10 March 2022.The holders of warrants have the right for each owned Warrant to subscribe one (1) new share in Veg of Lund to a price of SEK 11.06 per share. The number of warrants of series TO1 that intends to be exercised by members of the board of directors and major shareholders in the Company amounts

New micro-protein helps yeast cells cope with nutrient scarcity

Researchers from the University of Eastern Finland and the University of Montreal (Canada) have discovered that a micro-protein, which they named Nrs1, supports cell division and proliferation when nutrients are scarce. This result, published in PLOS Biology yesterday, sheds a new light on how evolution subtly reshapes the genomes of unicellular microorganisms, providing them with plasticity to adjust their growth and proliferation to ever-changing environments.  At the turn of the millennium, scientists became able to experimentally determine the DNA sequence of entire genomes. They

Successful review of HAMLET Pharma by the EU Horizon 2020 program

Hamlet Pharma has recently delivered its 18-month report to the European Union’s Horizon 2020 program. In their response, the EU states that the project has “fully achieved its objectives and milestones for the period” and “remains in line with the objectives”.The report summarizes the results in four parts. 1. The successful conclusion of the Phase I/II study. The report states that “the results demonstrated good safety and efficacy, which is very encouraging and supports the continued development of Alpha1H towards a Phase III trial”. 2. Transfer of the drug manufacturing

Kemira Oyj: Manager’s transaction; Jukka Hakkila has received Kemira’s shares related to Performance Share Plan

Kemira Oyj, Managers' transactions, March 4, 2022 at 10.05 am (EET)Kemira Oyj: Manager’s transaction; Jukka Hakkila has received Kemira’s shares related to Performance Share Plan  This is the notification according to the EU Market Abuse Regulation that Jukka Hakkila  has received Kemira shares related to the Performance Share Plan. Detailed information about the transaction is given below. Person subject to the notification requirementName: Hakkila, JukkaPosition: Other senior managerIssuer: Kemira OyjLEI: 74370031Y7RK5H88CQ48 Notification type: INITIAL NOTIFICATION

Kemira Oyj: Manager’s transaction; Matthew Pixton has received Kemira’s shares related to Performance Share Plan

Kemira Oyj, Managers' transactions, March 4, 2022 at 10.05 am (EET)Kemira Oyj: Manager’s transaction; Matthew Pixton has received Kemira’s shares related to Performance Share Plan  This is the notification according to the EU Market Abuse Regulation that Matthew Pixton  has received Kemira shares related to the Performance Share Plan. Detailed information about the transaction is given below. Person subject to the notification requirementName: Pixton, MatthewPosition: Other senior managerIssuer: Kemira OyjLEI: 74370031Y7RK5H88CQ48Notification type: INITIAL NOTIFICATION

Kemira Oyj: Manager’s transaction; Esa-Matti Puputti has received Kemira’s shares related to Performance Share Plan

Kemira Oyj, Managers' transactions, March 4, 2022 at 10.05 am (EET)Kemira Oyj: Manager’s transaction; Esa-Matti Puputti has received Kemira’s shares related to Performance Share Plan  This is the notification according to the EU Market Abuse Regulation that Esa-Matti Puputti has received Kemira shares related to the Performance Share Plan. Detailed information about the transaction is given below. Person subject to the notification requirementName: Puputti, Esa-MattiPosition: Other senior managerIssuer: Kemira OyjLEI: 74370031Y7RK5H88CQ48Notification type: INITIAL

Kemira Oyj: Manager’s transaction; Jari Rosendal has received Kemira’s shares related to Performance Share Plan

Kemira Oyj, Managers' transactions, March 4, 2022 at 10.05 am (EET)Kemira Oyj: Manager’s transaction; Jari Rosendal has received Kemira’s shares related to Performance Share Plan  This is the notification according to the EU Market Abuse Regulation that Jari Rosendal  has received Kemira shares related to the Performance Share Plan. Detailed information about the transaction is given below. Person subject to the notification requirementName: Rosendal, JariPosition: Chief Executive OfficerIssuer: Kemira OyjLEI: 74370031Y7RK5H88CQ48 Notification type: INITIAL

Kemira Oyj: Manager’s transaction; Petri Castrén has received Kemira’s shares related to Performance Share Plan

Kemira Oyj, Managers' transactions, March 4, 2022 at 10.05 am (EET)Kemira Oyj: Manager’s transaction; Petri Castrén has received Kemira’s shares related to Performance Share Plan  This is the notification according to the EU Market Abuse Regulation that Petri Castrén  has received Kemira shares related to the Performance Share Plan. Detailed information about the transaction is given below. Person subject to the notification requirementName: Castrén, PetriPosition: Chief Financial OfficerIssuer: Kemira OyjLEI: 74370031Y7RK5H88CQ48Notification type: INITIAL NOTIFICATION

Kemira Oyj: Manager’s transaction; Kim Poulsen has received Kemira’s shares related to Performance Share Plan

Kemira Oyj, Managers' transactions, March 4, 2022 at 10.05 am (EET)Kemira Oyj: Manager’s transaction; Kim Poulsen has received Kemira’s shares related to Performance Share Plan  This is the notification according to the EU Market Abuse Regulation that Kim Poulsen has received Kemira shares related to the Performance Share Plan. Detailed information about the transaction is given below. Person subject to the notification requirementName: Poulsen, KimPosition: Other senior managerIssuer: Kemira OyjLEI: 74370031Y7RK5H88CQ48 Notification type: INITIAL NOTIFICATION

Kemira Oyj: Manager’s transaction; Antti Salminen has received Kemira’s shares related to Performance Share Plan

Kemira Oyj, Managers' transactions, March 4, 2022 at 10.05 am (EET)Kemira Oyj: Manager’s transaction; Antti Salminen has received Kemira’s shares related to Performance Share Plan  This is the notification according to the EU Market Abuse Regulation that Antti Salminen has received Kemira shares related to the Performance Share Plan. Detailed information about the transaction is given below. Person subject to the notification requirementName: Salminen, AnttiPosition: Other senior managerIssuer: Kemira OyjLEI: 74370031Y7RK5H88CQ48 Notification type: INITIAL NOTIFICATION

Kemira Oyj: Manager’s transaction; Eeva Salonen has received Kemira’s shares related to Performance Share Plan

Kemira Oyj, Managers' transactions, March 4, 2022 at 10.05 am (EET)Kemira Oyj: Manager’s transaction; Eeva Salonen has received Kemira’s shares related to Performance Share Plan  This is the notification according to the EU Market Abuse Regulation that Eeva Salonen has received Kemira shares related to the Performance Share Plan. Detailed information about the transaction is given below. Person subject to the notification requirementName: Salonen, EevaPosition: Other senior managerIssuer: Kemira OyjLEI: 74370031Y7RK5H88CQ48 Notification type: INITIAL NOTIFICATION

Kemira Performance Share Plan - directed share issue

Kemira Oyj, Stock Exchange Release, March 4, 2022 at 10.00 am (EET)Kemira Performance Share Plan - directed share issue The Board of Directors of Kemira has on February 10, 2022 decided on a directed share issue related to the reward payment for the shares earned under Kemira’s performance share plan 2019-2023.  In the share issue, 221,128 Kemira shares held by the company have been conveyed on March 4, 2022 without consideration to 76 key employees participating in Kemira’s performance period 2019-2021 in accordance with the terms and conditions of the plan. More detailed information

PLAGAZI AB (PUBL) AND INLANDSBANAN AB SIGNS LETTER OF INTENT FOR DEVELOPMENT OF LOCALLY PRODUCED GREEN HYDROGEN

Plagazi AB (publ) (“Plagazi” or the “Company”) has signed a letter of intent ("LOI") together with Inlandsbanan AB (“IBAB”) with the aim of cooperating on the production and distribution of green hydrogen based on the extraction of hydrogen from non-recyclable waste.Inlandsbanan is a 1000 km long railway that stretches from Gällivare to Mora owned by the Swedish state and was built as a transport link to and from Sweden's most commodity-rich regions with the aim of increasing opportunities for exploitation in northern Sweden. Inlandsbanan is managed by IBAB as infrastructure manager, which

Arto Räty appointed Senior Advisor and leader of New Context group at Miltton

Lieutenant General Arto Räty moves to Miltton as Senior Advisor and leader of the New Context group. Räty has most recently worked as a member of the management team of the energy company Fortum and before that, for example, as Chief of Staff of the Finnish Ministry of Defence, Director of National Defence Courses and Chairman of the Security Committee.Räty has a unique expertise in foreign and security policy, international relations, strategic planning, international crisis management, and business and societal interactions. “The pillars of security in Europe and the international

Teleste Corporation: Managers´ Transactions – Harju

TELESTE CORPORATION   MANAGERS' TRANSACTIONS 4.3.2022 AT 10:00 EET Teleste Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Esa Harju Position: Chief Executive Officer Issuer: Teleste Oyj LEI: 743700CJRQRU0007GN59 Notification type: INITIAL NOTIFICATION Reference number: 10797/4/4 ____________________________________________ Transaction date: 2022-03-03 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009007728 Nature of the transaction: ACQUISITION

BioStock: Cereno Scientific strengthens IPR in Europe

Swedish biotech Cereno Scientific currently has three patent families protecting its lead drug candidate CS1. Combined, the three families cover most major markets around the world. This week, the company has announced being granted a patent belonging to the second patent family in Europe. This means that now two of the three patent families are covering the European market.Read the article at biostock.se: https://www.biostock.se/en/2022/03/cereno-scientific-strengthens-ipr-in-europe/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Inhalation Sciences receives new order worth 23 500 Euro from RISE, the Research Institute of Sweden

(Stockholm, 4 March 2022) Inhalation Sciences (ISAB) has received a new order worth 23 500 Euro from a returning customer – RISE, the Research Institute of Sweden, one of the country’s leading research bodies. RISE is purchasing ISAB’s Nebulizer Aerosol Generator, which enables precise dry powder-like aerosol to be generated from liquid solutions when mounted onto PreciseInhale®. RISE carries out a wide range of international research projects and collaborations, many funded by national and European public bodies.The new order, worth 23 500 Euro, is for ISAB’s Nebulizer Aerosol Generator

Notice of Annual General Meeting of Husqvarna AB (publ)

The shareholders of Husqvarna AB (publ) are hereby invited to participate in the 2022 Annual General Meeting (“AGM”), which will be held on Thursday, April 7, 2022. Due to the ongoing Covid-19 situation, the AGM will be conducted in accordance with so called mail-in procedures, meaning that shareholders and representatives will not be able attend the AGM in person. Instead, shareholders can only participate in the AGM by voting and submitting questions in advance pursuant to the instructions described below.In order to participate in the AGM via mail voting, a shareholder must: 1. a.

Changes in Musti Group’s Management Team

Musti Group plc                        Stock Exchange Release    4 March 2022 at 9.30 a.m. Changes in Musti Group’s Management Team Musti Group has today restructured its Group Management Team making the following appointments. Daniel Pettersson to take responsibility for Sweden and Finland markets Daniel Pettersson has been appointed as Head of Sweden and Finland (previously Country Director, Sweden).  In his expanded role, Pettersson will be responsible for management and the ongoing development of the company’s store operations in Sweden and Finland commencing 1 April 2022.

Divio Technologies AB (publ) Year-end report 2021 - Grows Net sales by 38%

Divio Technologies AB (Publ) decision of allocating significant resources into sales and implementing new sales strategies shows great results. A strong start and continued growth throughout the year. Net sales increased by 38 % compared to the same period 2020.Summary Of The Year-End Report  For The Period 1 July 2021 To 31 December 2021 · MRR in December increased by 8% to 144 (133) KUSD · Net sales increased by 38% to 7,607 (5,501) KSEK  · Subscription revenue increased by 20% to 7,270 (6,047) KSEK · Loss decreased to -5,619 (-8,413) KSEK · Earnings per share before

Transactions for persons discharging managerial responsibilities

Transactions for persons discharging managerial responsibilities: CEO Michael T Andersen and CFO Peter Klovgaard-Jørgensen receive shares in H+H International A/S under matching share programme from 2019 H+H International A/S has received notification pursuant to article 19 of EU Regulation no. 596/2014 of the below transaction(s) related to shares or other financial instruments in H+H International A/S made by persons discharging managerial responsibilities in H+H International A/S or persons closely related to them. 1. Details of the person discharging managerial responsibilities/

Finnair Cancels the General Meeting Convened to be Held on Thursday 24 March 2022 and Publishes a New Notice to the Annual General Meeting to be Held on Thursday 7 April 2022

Finnair Plc                              Stock Exchange Release                     4 March 2022 at 9.05 a.m. EET Finnair Plc earlier today announced changes concerning the proposal of the Shareholders' Nomination Board to the Annual General Meeting on the election of the Chair and members of the Board of Directors by. As the Annual General Meeting will be held in accordance with the temporary legislative act (375/2021), the company must, due to the changed proposal, issue a new notice to the Annual General Meeting and repeat the advance procedures related to the Annual General Meeting.

Faron to Present at Upcoming Conferences

Faron Pharmaceuticals Ltd. ("Faron")   Faron to Present at Upcoming Conferences   Press Release, March 4, 2022 at 02:00 AM (EST) / 07:00 AM (GMT) / 09:00 AM (EET)   TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announced that it will present at the following conferences in March:   · Redeye Investor Forum - Tuesday, March 8 · BioCapital

There are no items matching the current filter
There are no more items matching the current filter
Back to top